Cargando…

Infection profile of immune-modulatory drugs used in autoimmune diseases: analysis of summary of product characteristic data

OBJECTIVE: Serious infection remains a concern when prescribing immune-modulatory drugs for immune-mediated inflammatory diseases. The ‘summary of product characteristics’ (SmPCs) provide information on adverse events for example, infections, from clinical trials and postmarketing pharmacovigilance....

Descripción completa

Detalles Bibliográficos
Autores principales:	Dey, Mrinalini, Bechman, Katie, Zhao, Sizheng, Fragoulis, George E, Smith, Catherine, Cope, Andrew, Nikiphorou, Elena, Hyrich, Kimme L, Galloway, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Infections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685189/ https://www.ncbi.nlm.nih.gov/pubmed/36418084 http://dx.doi.org/10.1136/rmdopen-2022-002621

Ejemplares similares

Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
por: Fragoulis, George E, et al.
Publicado: (2022)

Hidradenitis suppurativa: infection, autoimmunity, or both?
por: Constantinou, Costas A, et al.
Publicado: (2019)

Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease
por: Bechman, Katie, et al.
Publicado: (2023)

The infection risks of JAK inhibition
por: Adas, Maryam A., et al.
Publicado: (2021)

The immunosuppressed traveler: infection risks with autoimmunity and immunosuppression, vaccinations, and general travel advice
por: Allen, Victoria, et al.
Publicado: (2020)

Beverages in Rheumatoid Arthritis: What to Prefer or to Avoid
por: Dey, Mrinalini, et al.
Publicado: (2020)

Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management
por: Dey, Mrinalini, et al.
Publicado: (2021)

Google search data as a novel adjunct to patient and public involvement in rheumatology research
por: Dey, Mrinalini, et al.
Publicado: (2020)

COVID-19 and Kawasaki disease: an analysis using Google Trends
por: Dey, Mrinalini, et al.
Publicado: (2020)

SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry
por: Lawson-Tovey, Saskia, et al.
Publicado: (2022)

A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis
por: Bechman, Katie, et al.
Publicado: (2020)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register
por: Bechman, Katie, et al.
Publicado: (2020)

Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register
por: Bechman, Katie, et al.
Publicado: (2020)

Pulmonary manifestations in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: a systematic review
por: Kouranloo, Koushan, et al.
Publicado: (2023)

The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
por: Bechman, Katie, et al.
Publicado: (2019)

Corrigendum to “The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors” [Pharmacol. Res. 147 (2019) 104392]
por: Bechman, Katie, et al.
Publicado: (2020)

Late-Onset Psoriatic Arthritis: Are There Any Distinct Characteristics? A Retrospective Cohort Data Analysis
por: Gialouri, Chrysoula G., et al.
Publicado: (2023)

Methotrexate-Associated Pneumonitis and Rheumatoid Arthritis-Interstitial Lung Disease: Current Concepts for the Diagnosis and Treatment
por: Fragoulis, George E., et al.
Publicado: (2019)

Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial
por: Bechman, Katie, et al.
Publicado: (2018)

Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis
por: Taylor, Thomas R.P., et al.
Publicado: (2021)

Oral Microbiome Characteristics in Patients With Autoimmune Hepatitis
por: Rao, Benchen, et al.
Publicado: (2021)

Modulatory Effect of Trypanosoma cruzi Infective Stages in Different Dendritic Cell Populations in vitro
por: Gutierrez, Brenda Celeste, et al.
Publicado: (2020)

Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases
por: Fragoulis, George E, et al.
Publicado: (2022)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China
por: Zhu, Lan, et al.
Publicado: (2020)

Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
por: Andreica, Ioana, et al.
Publicado: (2022)

The safety of JAK-1 inhibitors
por: Clarke, Benjamin, et al.
Publicado: (2021)

Microparticles That Form Immune Complexes as Modulatory Structures in Autoimmune Responses
por: Burbano, Catalina, et al.
Publicado: (2015)

The Modulatory Roles of N-glycans in T-Cell-Mediated Autoimmune Diseases
por: Chien, Ming-Wei, et al.
Publicado: (2018)

SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
por: Liew, Jean, et al.
Publicado: (2022)

Large joints are progressively involved in rheumatoid arthritis irrespective of rheumatoid factor status—results from the early rheumatoid arthritis study
por: Zhao, Sizheng Steven, et al.
Publicado: (2021)

Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network
por: Galmiche, Simon, et al.
Publicado: (2023)

Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature
por: Nikiphorou, Elena, et al.
Publicado: (2016)

Association between social deprivation and disease activity in rheumatoid arthritis: a systematic literature review
por: Dey, Mrinalini, et al.
Publicado: (2022)

Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?
por: Laster, Andrew J, et al.
Publicado: (2022)

Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti‑TNF therapy: results from the British Society for Rheumatology Biologics Register
por: Davies, Rebecca, et al.
Publicado: (2011)

Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies
por: Tani, Chiara, et al.
Publicado: (2021)

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
por: DiIorio, Michael, et al.
Publicado: (2022)

What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?
por: Humphreys, Jenny, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fkiqqlg7obhbeo97dk66ibm3tk